CpG‐ODN‐stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen‐specific antitumour immunity in a HPV 16 E7‐associated animal tumour model
Open Access
- 16 April 2004
- journal article
- Published by Wiley in Immunology
- Vol. 112 (1) , 117-125
- https://doi.org/10.1111/j.1365-2567.2004.01851.x
Abstract
We previously reported that both E7 and CpG-oligodeoxynucleotide (ODN) are required for protecting animals from human papillomavirus (HPV) 16 E7-associated tumour challenge. Here we investigate dendritic cells (DC)-based approach in this protection. In the study, we isolated bone marrow-derived DC and stimulated DC with E7 and ODN. In vitro stimulation of DC with E7 plus ODN resulted in more production of interleukin-12, as compared to that with E7 or ODN alone. Further injection with E7+ODN-stimulated DC resulted in more significant tumour protection, as compared to stimulation with E7 or ODN alone. We further evaluated the levels of immune responses induced by DC stimulated with E7+ODN. We observed little enhancement of E7-specific antibody and T helper cell proliferative responses by E7+ODN stimulation, as compared to E7 stimulation. However, there was some enhancement of interferon-gamma (IFN-gamma) production from CD4+ T cells and a more significant production of IFN-gamma from CD8+ T cells by E7+ODN stimulation, as compared to E7 stimulation alone. This was consistent with intracellular IFN-gamma staining levels of CD8+ T cells. Tumour protection further appeared to be mediated by CD8+ T cells, as determined by in vivo T-cell depletion. Thus, these data suggest that upon ODN stimulation DC might function as a potent adjuvant for E7 protein delivery for induction of protective cellular immunity against HPV E7-associated tumour challenge.Keywords
This publication has 54 references indexed in Scilit:
- A Therapy Modality Using Recombinant IL-12 Adenovirus plus E7 Protein in a Human Papillomavirus 16 E6/E7-Associated Cervical Cancer Animal ModelHuman Gene Therapy, 2003
- Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapyEuropean Journal of Immunology, 2002
- Cancer Immunotherapy Using Sindbis Virus Replicon Particles Encoding a VP22–Antigen FusionHuman Gene Therapy, 2002
- Modulation of Cellular Responses by Plasmid CD40L: CD40L Plasmid Vectors Enhance Antigen-Specific Helper T Cell Type 1 CD4+T Cell-Mediated Protective Immunity against Herpes Simplex Virus Type 2in VivoHuman Gene Therapy, 2001
- Enhanced Therapeutic Efficacy of Tumor RNA-Pulsed Dendritic Cells after Genetic Modification with LymphotactinHuman Gene Therapy, 1999
- CELLULAR RESPONSES TO INTERFERON-γAnnual Review of Immunology, 1997
- CpG motifs in bacterial DNA trigger direct B-cell activationNature, 1995
- Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cellsEuropean Journal of Immunology, 1993
- Antiviral actions of interferon interferon-regulated cellular proteins and their surprisingly selective antiviral activitiesVirology, 1991
- The Dendritic Cell System and its Role in ImmunogenicityAnnual Review of Immunology, 1991